Akari Therapeutics, Plc (AKTX) — 1.5 (+0.01)
Key Metrics & Ratings
- symbol AKTX
- Rev/Share 0.0
- Book/Share 0.0287
- PB 92.7413
- Debt/Equity 0.0
- CurrentRatio 1.1473
- ROIC -5.065
- MktCap 15038177.0
- FreeCF/Share -0.3444
- PFCF -0.6993
- PE -23.8196
- Debt/Assets 0.0
- DivYield 0
- ROE -1.8984
- Rating B
- Score 3.0
- Recommendation Neutral
- P/E Score 2.0
- DCF Score 5.0
- P/B Score 5.0
- D/E Score 3.0
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
Published: April 15, 2024 by: GlobeNewsWire
Sentiment: Neutral
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari Chief Scientific Officer Miles Nunn will provide an overview of the data in a poster presentation on Sunday, May 5 from 1:00 to 2:45 pm PT.
Read More
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
Published: April 01, 2024 by: GlobeNewsWire
Sentiment: Neutral
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.
Read More
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
Published: January 02, 2024 by: GlobeNewsWire
Sentiment: Neutral
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.
Read More
Akari Therapeutics to Present at Biotech Showcase 2024
Published: December 14, 2023 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.
Read More
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.
Published: December 01, 2023 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors.
Read More
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
Published: November 16, 2023 by: GlobeNewsWire
Sentiment: Neutral
Positive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin clinical development with Phase 1 single and multiple ascending dose (SAD/MAD) testing to evaluate safety and pharmacokinetics/pharmacodynamics (PK/PD) of long-acting PAS-nomacopan Positive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin clinical development with Phase 1 single and multiple ascending dose (SAD/MAD) testing to evaluate safety and pharmacokinetics/pharmacodynamics (PK/PD) of long-acting PAS-nomacopan
Read More
About Akari Therapeutics, Plc (AKTX)
- IPO Date 2014-01-06
- Website https://www.akaritx.com
- Industry Biotechnology
- CEO Dr. Samir Rashmikant Patel M.D.
- Employees 9